A randomized trial of 24 versus 48 weeks of peginterferon a-2a plus ribavirin in Egyptian patients with hepatitis C virus genotype 4 and rapid viral response | Zendy

Hisham R ElKhayat | Zendy; Yasser Fouad | Zendy; Hussein El Amin | Zendy

Open Access

A randomized trial of 24 versus 48 weeks of peginterferon a-2a plus ribavirin in Egyptian patients with hepatitis C virus genotype 4 and rapid viral response

Author(s) -

Hisham R ElKhayat,

Yasser Fouad,

Hussein El Amin

Publication year - 2012

Publication title -

tropical gastroenterology

Language(s) - English

Resource type - Journals

eISSN - 2320-5792

pISSN - 0250-636X

DOI - 10.7869/tg.2012.27

Subject(s) - ribavirin , medicine , adverse effect , gastroenterology , hepatitis c virus , viral load , randomized controlled trial , genotype , pegylated interferon , hepatitis c , immunology , virus , biology , biochemistry , gene

Little data is available regarding the 24-week therapy with pegylated interferon and ribavirin in Egyptian patients with hepatitis C virus (HCV) genotype 4 infection. We aimed to investigate the efficacy of 24-week versus 48-week peginterferon alpha-2a plus ribavirin therapy in patients with HCV genotype 4 infection with with rapid virological response.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research